Lymphoma Hub Satellite Symposium—Summary and roundtable discussion

At this year’s European School of Haematology (ESH) ‘2nd How to Diagnose and Treat: Lymphoma’ conference, the Lymphoma Hub hosted a virtual Satellite Symposium on the management and treatment of patients with relapsed/refractory (R/R) lymphoma.

The symposium brought together a panel of international experts, who gave their opinion on two distinct patient cases, presented in Figure 1. Click to see the presentations by Kieron Dunleavy, Marie José Kersten, Astrid Pavlovsky and Francesc Bosch.

Figure 1. A R/R DLBCL patient case and B R/R CLL patient case

ASCT, autologous hematopoietic stem cell transplantation; BM, bone marrow; CAR, chimeric antigen receptor; CLL, chronic lymphocytic leukemia; DHAP, dexamethasone + high-dose cytarabine + cisplatin; DLBCL, diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; FISH, fluorescence in situ hybridization; IGHV, immunoglobulin heavy chain variable region; LDH, lactate dehydrogenase; R-CHOP, rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone; R/R, relapsed and/or refractory; WBC, white blood cell. 

Following a diverse selection of presentations by the four panelists, there was an exciting roundtable discussion answering any questions submitted by the audience; watch it below.

In the lead up to the virtual symposium, the Lymphoma Hub conducted a series of Twitter polls to gain insight into the audience’s understanding of, and interests within, the field of R/R lymphoma (Figure 2). Take a look at the Lymphoma Hub symposium content in our Twitter moment.

Figure 2. Results of the Lymphoma Hub Satellite Symposium Twitter polls 

allo-SCT, allogeneic stem cell transplant; CAR, chimeric antigen receptor; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; R/R relapsed and/or refractory. 

Below, Lymphoma Hub Chair Gilles Salles shares the highlights from the symposium.